Summary
Merbarone was developed to clinical trial stage on the basis of its ‘curative’ activity against P388 and L1210 leukemias and moderate activity against B16 melanoma and M5076 sarcoma. Its activity appears to be schedule-dependent favoring a longer duration of administration. The mechanism of action of merbarone is not yet established but it does induce single strand breaks in DNA apparently without binding to DNA.
The pharmacokinetic data in the dog indicate that clearance mechanisms may be saturable. Merbarone is hydroxylated at the 4′ position in the rat, mouse and dog, and glucuronidated in the dog. Parent drug and the hydroxy metabolite are excreted in the urine. If saturable clearance mechanisms also pertain to man, this will mean that infusion rate (and therefore steady state concentrations reached) may be a significant factor in determining acute toxicity.
Preclinical toxicology studies revealed that major target tissues are in the lymphoid organs, bone marrow, gastrointestinal tract and kidney. Some behavioral signs of reversible central nervous system toxicity were observed.
Phase I trials have commenced using only a 5-day continuous intravenous infusion schedule based on the preclinical data. The pharmacokinetic information from these trials will be crucial for further clinical development of the compound, including selection of the optimal schedule(s) for phase II/III evaluation.
Similar content being viewed by others
References
Driscoll JS, Melnick NR, Quinn FT, Lomax N, Davignon JP, Ing R, Abbott BJ, Congleton G, Dudeck L: Psychotropic drugs as potential antitumor agents: A selective screening study. Cancer Treat Rep 62: 45–74, 1978
Brewer AD, Minatelli JA, Plowman J, Paull KD, Narayanan VL: 5-(N-phenyl-carboxamido)-2-thiobarbituric acid (NSC 336628), a novel potential antitumor agent. Biochem Pharmacol 34: 2047–2050, 1985
Kemmenoe B, Malspeis L: Distribution of [2-14C]-merbarone in mice by autoradiography of whole-body cryosections. (Abstract) Proc Am Assoc Cancer Res 27: 402, 1986
Clinical Brochure for Merbarone, prepared by the Division of Cancer Treatment, National Cancer Institute, October, 1985
Cooney DA, Covey JM, Kang GJ, Dalal M, McMahon JF, Johns DG: Initial mechanistic studies with merbarone (NSC 336628). Biochem Pharmacol 34: 3395–3398, 1985
Shoemaker R, Wolpert-DeFilippes M, Plowman J, Abbott B, Venditti J, Trader M, Griswold D, Gerlach J, Ling V: Pleotropic resistance and drug development. In: T.Hall (ed) Cancer Drug Resistance. Alan R. Liss, Inc. (in press)
Chou TH, Yost C: Adriamycin resistance in murine leukemia P388 cells and increased DNA repair. (Abstract) Proc Am Assoc Cancer Res 26: 217, 1985
Liao JT, Collins WT, Karcher RV, Hiles RA, Frick S, Cibinic J, Grieshaber CK, Kastello MD: Preclinical studies of merbarone (NSC-336628) in beagle dogs: effect of dosing schedule on toxicity. (Abstract) Proc Am Assoc Cancer Res 27: 418, 1986
Malspeis L, Lyon ME, DeSouza JJV, Staubus AE: Preclinical pharmacology studies of merbarone (NSC 336628). (Abstract) Proc Am Assoc Cancer Res 27: 402, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Glover, A., Chun, H.G., Kleinman, L.M. et al. Merbarone: an antitumor agent entering clinical trials. Invest New Drugs 5, 137–143 (1987). https://doi.org/10.1007/BF00203538
Issue Date:
DOI: https://doi.org/10.1007/BF00203538